Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences Licenses Probe Technologies to Celera Diagnostics

NEW YORK, Feb. 10 (GenomeWeb News) - Epoch Biosciences has licensed two DNA probe technologies to Celera Diagnostics, the company said today.


Under the worldwide non-exclusive license, Celera can manufacture, sell, and distribute TaqMan probes that use Epoch's MGB minor groove binder and Eclipse Dark quencher technologies in diagnostics products for infectious diseases. In exchange, Epoch will receive license fees and royalties on sales of these products.


According to Bothell, Wash.-based Epoch, this is its first deal in the human diagnostics area.



The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.